Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The objective of this phase III study is to compare the efficacy and safety of sorafenib monotherapy plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients with relapsed or refractory advanced predominantly non squamous NSCLC after 2 or 3 prior treatment regimens for advanced disease. The primary efficacy variable is overall survival (OS).
Inclusion criteria
- Non-small cell lung carcinoma in patients with predominantly non-squamous cell carcinoma histology